Payment overview · 2025
General Payments
$203.97
9 reported records · 6 companies
Healthcare provider profile · identity verified
Samuel David Patrick Mcelroy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAVANNAH, GA · NPI 1023302544
Verified facts
What the public records show
CMS Open Payments records show Samuel David Patrick Mcelroy, MD received $203.97 in general payments during 2025 across 9 reported records.
Astellas Pharma US Inc accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $59.71 | 29.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.58 | 25.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.34 | 14.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.89 | 10.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.17 | 10.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.28 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.97 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $59.71 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.58 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 941 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 643 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 101 |
| Losartan Potassium | Losartan Potassium | 371 | 106 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 370 | 108 |
| Omeprazole | Omeprazole | 324 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 74 |
| Metformin Hcl Er | Metformin Hcl | 212 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 61 |
| Gabapentin | Gabapentin | 176 | 60 |
| Trulicity | Dulaglutide | 173 | 32 |
| Allopurinol | Allopurinol | 158 | 42 |
| Ezetimibe | Ezetimibe | 153 | 53 |
| Furosemide | Furosemide | 152 | 52 |
| Ozempic | Semaglutide | 152 | 35 |
| Famotidine | Famotidine | 150 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 44 |
| Metformin Hcl | Metformin Hcl | 136 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 38 |
| Lisinopril | Lisinopril | 129 | 44 |
| Tramadol Hcl | Tramadol Hcl | 127 | 35 |
| Eliquis | Apixaban | 126 | 34 |
| Carvedilol | Carvedilol | 125 | 39 |
| Chlorthalidone | Chlorthalidone | 119 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 33 |
| Potassium Chloride | Potassium Chloride | 108 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Simvastatin | Simvastatin | 105 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 29 |
| Montelukast Sodium | Montelukast Sodium | 97 | 32 |
| Valsartan | Valsartan | 97 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 30 |
| Trazodone Hcl | Trazodone Hcl | 82 | 27 |
| Mounjaro | Tirzepatide | 77 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 25 |
| Finasteride | Finasteride | 74 | 22 |
| Lorazepam | Lorazepam | 70 | 15 |
| Synthroid | Levothyroxine Sodium | 66 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 15 |
| Jardiance | Empagliflozin | 63 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 15 |
| Sertraline Hcl | Sertraline Hcl | 57 | 18 |
| Alprazolam | Alprazolam | 55 | 13 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Meloxicam | Meloxicam | 49 | 17 |
| Repatha Sureclick | Evolocumab | 47 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 12 |
| Prednisone | Prednisone | 46 | 32 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Celecoxib | Celecoxib | 40 | 13 |
| Spironolactone | Spironolactone | 39 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | 11 |
| Azelastine Hcl | Azelastine Hcl | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 12 |
| Atenolol | Atenolol | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 15 |
| Azithromycin | Azithromycin | 29 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 20 |
| Temazepam | Temazepam | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.97 · 9 records | Astellas Pharma US Inc | LEQVIO, Leqembi, OTEZLA, REPATHA, TZIELD, Veozah, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error